Similar articles

• Contra: "Anti-platelet therapy is an alternative to oral anticoagulation for atrial fibrillation".

  Apostolakis S, Shantsila E, Lip GY, Lane DA. Apostolakis S, et al. Thromb Haemost. 2009 Nov;102(5):914-5. doi: 10.1160/TH09-08-0563. Thromb Haemost. 2009. PMID: 19888529 No abstract available.
• Bleeding risk on warfarin among elderly patients with atrial fibrillation.

  Cowan A, Hylek EM. Cowan A, et al. J Am Coll Cardiol. 2010 Mar 2;55(9):932; author reply 932-3. doi: 10.1016/j.jacc.2009.11.037. J Am Coll Cardiol. 2010. PMID: 20185052 No abstract available.
• Bleeding rates in patients older than 90 years of age on vitamin K antagonist therapy for nonvalvular atrial fibrillation.

  Tincani E, Baldini P, Crowther MA, Zanasi A, Ferrari P, Cenci AM, Rioli G. Tincani E, et al. Blood Coagul Fibrinolysis. 2009 Jan;20(1):47-51. doi: 10.1097/MBC.0b013e32831be9da. Blood Coagul Fibrinolysis. 2009. PMID: 20523164
• Clinical practice. Care of patients receiving long-term anticoagulant therapy.

  Schulman S. Schulman S. N Engl J Med. 2003 Aug 14;349(7):675-83. doi: 10.1056/NEJMcp025373. N Engl J Med. 2003. PMID: 12917305 Review. No abstract available.
• Organ-specific bleeding patterns of anticoagulant therapy: lessons from clinical trials.

  Vanassche T, Hirsh J, Eikelboom JW, Ginsberg JS. Vanassche T, et al. Thromb Haemost. 2014 Nov;112(5):918-23. doi: 10.1160/TH14-04-0346. Epub 2014 Sep 4. Thromb Haemost. 2014. PMID: 25187203 Review.